Northstrive Fund II 致函建议 Bluejay 董事会评估收购针对难治性慢性咳嗽的I期就绪疗法资产

美股速递
Mar 11

Northstrive Fund II 已向 Bluejay Diagnostics Inc 董事会发出信函,建议其审慎评估一项潜在的收购机会。该收购标的为一种针对难治性慢性咳嗽的治疗性资产,目前已具备进入I期临床试验的条件。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10